Fentanil Aurobindo 100microgram

1. Classification and Chemical Overview

Fentanyl is a potent synthetic phenylpiperidine-derivative opioid analgesic. Under the Anatomical Therapeutic Chemical (ATC) classification system, it is indexed under N02AB03.

Chemically designated as $N$-(1-phenethylpiperidin-4-yl)-$N$-phenylpropanamide, fentanyl is a lipophilic compound highly suited to transdermal delivery. In United Kingdom clinical practice, Fentanyl Aurobindo 100 micrograms/hour is presented as a transdermal patch designed to release 100 micrograms of fentanyl per hour continuously over a 72-hour period. Under the Human Medicines Regulations 2012, fentanyl is classified as a Prescription Only Medicine (POM) and is controlled under Schedule 2 of the Misuse of Drugs Regulations 2001 (as amended).

2. Mechanism of Action and Pharmacodynamics

Fentanyl is a selective, high-affinity agonist at central and peripheral $\mu$-opioid receptors. It displays low affinity for $\kappa$– and $\delta$-opioid receptors.

Binding to the G-protein-coupled $\mu$-opioid receptor inhibits adenylyl cyclase activity, reduces intracellular cyclic AMP (cAMP), closes voltage-gated calcium channels, and opens inwardly rectifying potassium channels. This hyperpolarises primary afferent nociceptors and blocks the presynaptic release of excitatory neurotransmitters (such as substance P and glutamate) within the dorsal horn of the spinal cord and higher cerebral centers.

The primary clinical effects are central analgesia, sedation, euphoria, and respiratory depression. The analgesic dose-response relationship is direct; however, the risk of life-threatening respiratory depression scales in parallel with systemic concentration.

3. Approved UK Clinical Indications and Therapeutic Scope

Licensing by the Medicines and Healthcare products Regulatory Agency (MHRA) for transdermal fentanyl patches includes:

• Severe Chronic Pain (Adults): Management of severe chronic pain that can be adequately managed only with opioid analgesics in opioid-tolerant patients.

• Severe Chronic Intractable Pain (Paediatrics): Long-term management of severe chronic pain in opioid-tolerant paediatric patients aged 2 years and older.

Note on 100 micrograms/hour Dosage Strength: Transdermal fentanyl patches are strictly indicated only in patients who are considered opioid-tolerant. Opioid tolerance is clinically defined as receiving at least 60 mg oral morphine daily (or an equianalgesic dose of another opioid) for one week or longer. The 100 micrograms/hour patch represents the highest standard single patch strength available, corresponding to an approximate equivalent oral morphine dose of 240 mg to 300 mg daily.

NICE & BNF Guidance Context: National Institute for Health and Care Excellence (NICE) guidelines recommend transdermal fentanyl as an alternative strong opioid for patients with stable, severe chronic pain (such as advanced cancer pain) who experience intolerable side effects from oral morphine or who have severe swallowing difficulties and gastrointestinal impairment. It is strictly contraindicated in acute or post-operative pain.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Following application of the transdermal patch, fentanyl is absorbed continuously through the epidermis. A cutaneous depot forms in the upper skin layers before systemic absorption occurs. Minimal therapeutic concentrations appear within 6 to 12 hours, with peak plasma concentrations (Tmax​) achieved between 24 and 72 hours following initial application.

• Distribution: Fentanyl is rapidly distributed across tissues, with a high apparent volume of distribution (Vd​) ranging from $3\text{ to }10\text{ L/kg}$. Plasma protein binding is approximately 80% to 85% (primarily to α1​-acid glycoprotein and albumin). Fentanyl readily crosses the blood-brain barrier, placental barrier, and passes into human breast milk.

• Biotransformation: Fentanyl undergoes rapid and extensive hepatic biotransformation via Phase I oxidative $N$-dealkylation, mediated primarily by Cytochrome P450 3A4 (CYP3A4), to yield norfentanyl. Norfentanyl and other minor metabolites are inactive.

• Elimination: Approximately 75% of an administered dose is excreted in urine within 3 to 4 days, mainly as inactive metabolites, with less than 10% as unchanged drug. Approximately 9% is excreted in faeces. Following patch removal, systemic absorption from the skin depot continues; plasma concentrations decrease gradually with a terminal elimination half-life (t1/2​) of approximately 17 to 25 hours.

5. Physiological Effects and Adverse Event Spectrum

Fentanyl alters nociceptive transmission and central nervous system responsiveness, producing systemic analgesia, central respiratory depression, bradycardia, reduced gastrointestinal motility, and sphincter of Oddi constriction.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Somnolence, dizziness, headache, nausea, vomiting, constipation, hyperhidrosis, pruritus.

• Common ($\ge 1/100$ to $<1/10$): Hypersensitivity reactions, anorexia, insomnia, depression, anxiety, confusion, hallucinations, tremor, paraesthesia, vertigo, palpitations, tachycardia, hypertension, dyspnoea, diarrhoea, dry mouth, abdominal pain, dyspepsia, rash, erythema at application site, muscle spasms, urinary retention, fatigue, peripheral oedema, asthenia.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Agitation, disorientation, euphoria, hypoaesthesia, convulsions, bradycardia, cyanosis, hypotension, respiratory depression, paralytic ileus, eczema, dermatitis, application site reactions, erectile dysfunction, sexual dysfunction, body temperature changes.

• Rare ($\ge 1/10,000$ to $<1/1,000$): Miosis, apnoea, hypoventilation, subileus, application site vesicles/eczema.

• Frequency Unknown: Anaphylactic shock, androgen deficiency, opioid withdrawal symptoms, neonatal withdrawal syndrome.

6. Contraindications, Drug Interactions, and Clinical Precautions

Controindicazioni

• Hypersensitivity to fentanyl or patch adhesive components.

• Opioid-naive patients (severe risk of life-threatening respiratory depression).

• Acute pain, post-operative pain, or short-term pain conditions.

• Severe, acute respiratory depression or severe obstructive airways disease.

Key Drug Interactions

• CYP3A4 Inhibitors: Concomitant administration with CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin, clarithromycin, diltiazem, grapefruit juice) decreases fentanyl clearance, increasing plasma concentrations and the risk of fatal respiratory depression.

• CYP3A4 Inducers: Co-administration with CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin) enhances clearance, reducing analgesic efficacy and potentially triggering opioid withdrawal.

• CNS Depressants & Alcohol: Concomitant use with benzodiazepines, sedatives, hypnotics, general anaesthetics, phenothiazines, opioids, or alcohol significantly increases the risk of profound sedation, respiratory depression, coma, and death.

• Serotonergic Drugs (e.g., SSRIs, SNRIs, MAOIs): Co-administration may increase the risk of Serotonin Syndrome. Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of their cessation is contraindicated.

Clinical Precautions and Monitoring

• Accidental Exposure & Safe Disposal: Accidental exposure to used or unused patches (especially in children) can be fatal. Used patches must be folded with adhesive sides together and disposed of safely.

• Heat Application: External heat sources (e.g., heating pads, hot water bottles, electric blankets, saunas, hot tubs) increase temperature-dependent skin permeability and blood flow, dramatically increasing fentanyl release and systemic exposure. Patients must be warned against exposing the application site to direct heat.

• Fever: Patients developing severe fever must be monitored for signs of opioid toxicity due to increased transdermal absorption.

• Respiratory Depression & Tolerance: Baseline respiratory status, cognitive function, and bowel function must be monitored regularly. Abrupt discontinuation risks severe opioid withdrawal; gradual tapering is required.

• Renal and Hepatic Impairment: Fentanyl clearance is reduced in renal or hepatic dysfunction; close monitoring for toxicity is required.